SAN FRANCISCO, Oct. 25, 2021 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN), today announced that analyses from the global Phase 3 roxadustat clinical program will be presented at the American Society of Nephrology Kidney Week 2021 taking place virtually November 4 - 7, 2021. A total of 18 presentations...
SAN FRANCISCO, May 08, 2020 (GLOBE NEWSWIRE) — FibroGen, Inc. (NASDAQ: FGEN) will participate in the Bank of America Securities 2020 Health Care Conference that is being held virtually on May 12-14, 2020. Enrique Conterno, Chief Executive Officer, w… […]
FibroGen to Present Interim Phase 2 Data on Pamrevlumab in Subjects with Duchenne Muscular Dystrophy at the Parent Project Muscular Dystrophy 2019 Annual Conference
SAN FRANCISCO, June 28, 2019 (GLOBE NEWSWIRE) — FibroGen, Inc. (NASDAQ: FGEN), today announced that the company will present interim data on their open-label, single-arm Phase 2 trial evaluating pamrevlumab, a monoclonal antibody to connective tissu… […]
SAN FRANCISCO, June 16, 2021 (GLOBE NEWSWIRE) — FibroGen, Inc. (NASDAQ: FGEN) announced activation of an experimental arm in the Pancreatic Cancer Action Network’s (PanCAN) Precision PromiseSM adaptive trial platform evaluating pamrevlumab [and… […]